# CHA2DS2-VA Score for Atrial Fibrillation Stroke Risk
# Source: ESC Guidelines 2024

name: "CHA2DS2-VA Score"
name_de: "CHA2DS2-VA-Score"
specialty: Cardiology
specialty_de: "Kardiologie"
version: "2024-v1"
guideline_source: "ESC 2024"
reference: "ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2024;45(36):3314-3414. doi:10.1093/eurheartj/ehad123"
validation_status: "peer_reviewed"
description: "Stroke risk stratification in patients with atrial fibrillation"
description_de: "Schlaganfallrisiko-Stratifizierung bei Patienten mit Vorhofflimmern"

inputs:
  - field: "age"
    type: "number"
    label: "Age"
    label_de: "Alter"
    unit: "years"
    unit_de: "Jahre"
    min: 18
    max: 120
    points:
      - condition: ">= 75"
        points: 2
        label: "Age ≥75 years"
        label_de: "Alter ≥75 Jahre"
      - condition: ">= 65"
        points: 1
        label: "Age 65-74 years"
        label_de: "Alter 65-74 Jahre"
    help: "Age in years"
    help_de: "Alter in Jahren"
    required: true

  - field: "heart_failure"
    type: "boolean"
    label: "Congestive Heart Failure"
    label_de: "Herzinsuffizienz"
    points: 1
    help: "History of CHF or objective evidence of moderate to severe LV systolic dysfunction (e.g., LVEF ≤40%)"
    help_de: "Anamnese einer Herzinsuffizienz oder objektiver Nachweis einer mittel- bis schwergradigen LV-Dysfunktion (z.B. LVEF ≤40%)"
    required: true

  - field: "hypertension"
    type: "boolean"
    label: "Hypertension"
    label_de: "Hypertonie"
    points: 1
    help: "Blood pressure consistently >140/90 mmHg or on antihypertensive treatment"
    help_de: "Blutdruck durchgehend >140/90 mmHg oder antihypertensive Behandlung"
    required: true

  - field: "diabetes"
    type: "boolean"
    label: "Diabetes Mellitus"
    label_de: "Diabetes mellitus"
    points: 1
    help: "Fasting glucose >125 mg/dL (7.0 mmol/L) or on hypoglycemic treatment"
    help_de: "Nüchternglukose >125 mg/dL (7,0 mmol/L) oder unter blutzuckersenkender Behandlung"
    required: true

  - field: "stroke_tia"
    type: "boolean"
    label: "Prior Stroke, TIA, or Thromboembolism"
    label_de: "Schlaganfall, TIA oder Thromboembolie in der Anamnese"
    points: 2
    help: "Previous stroke, transient ischemic attack, or systemic thromboembolism"
    help_de: "Früherer Schlaganfall, transitorische ischämische Attacke oder systemische Thromboembolie"
    required: true

  - field: "vascular_disease"
    type: "boolean"
    label: "Vascular Disease"
    label_de: "Gefäßerkrankung"
    points: 1
    help: "Prior myocardial infarction, peripheral artery disease, or aortic plaque"
    help_de: "Früherer Myokardinfarkt, periphere arterielle Verschlusskrankheit oder Aortenplaque"
    required: true

interpretation:
  - score: 0
    risk: "Low"
    risk_de: "Niedrig"
    risk_level: Low
    recommendation: "Anticoagulation not routinely recommended. Consider if additional stroke risk factors are present. Annual stroke risk: 0-0.2%"
    recommendation_de: "Antikoagulation nicht routinemäßig empfohlen. Erwägen, wenn zusätzliche Schlaganfallrisikofaktoren vorhanden sind. Jährliches Schlaganfallrisiko: 0-0,2%"
    details: "Very low risk. May consider antiplatelet therapy or no antithrombotic therapy based on bleeding risk."
    details_de: "Sehr niedriges Risiko. Thrombozytenaggregationshemmung oder keine antithrombotische Therapie je nach Blutungsrisiko erwägen."

  - score: 1
    risk: "Low-Moderate"
    risk_de: "Niedrig-Mittel"
    risk_level: Moderate
    recommendation: "Consider oral anticoagulation. Individualized decision based on patient preference, bleeding risk (HAS-BLED), and shared decision-making. Annual stroke risk: 0.6-2.0%"
    recommendation_de: "Orale Antikoagulation erwägen. Individuelle Entscheidung basierend auf Patientenpräferenz, Blutungsrisiko (HAS-BLED) und gemeinsamer Entscheidungsfindung. Jährliches Schlaganfallrisiko: 0,6-2,0%"
    details: "ESC recommends considering OAC for males with score ≥1 and females with score ≥2"
    details_de: "ESC empfiehlt OAK bei Männern mit Score ≥1 und Frauen mit Score ≥2 zu erwägen"

  - score: "≥2"
    risk: "Moderate-High"
    risk_de: "Mittel-Hoch"
    risk_level: High
    recommendation: "Oral anticoagulation recommended unless contraindicated (ESC Class I, Level A). Prefer DOAC (dabigatran, rivaroxaban, apixaban, edoxaban) over VKA in DOAC-eligible patients. Annual stroke risk: >2.2%"
    recommendation_de: "Orale Antikoagulation empfohlen, außer kontraindiziert (ESC Klasse I, Level A). DOAK (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) gegenüber VKA bei DOAK-geeigneten Patienten bevorzugen. Jährliches Schlaganfallrisiko: >2,2%"
    details: "High risk. Strong indication for OAC. Consider HAS-BLED score for bleeding risk assessment."
    details_de: "Hohes Risiko. Starke Indikation für OAK. HAS-BLED-Score zur Blutungsrisikoabschätzung erwägen."

metadata:
  tags: "atrial fibrillation, stroke risk, anticoagulation, DOAC, NOAC, warfarin, ESC guidelines"
  keywords_de: "Vorhofflimmern, Schlaganfallrisiko, Antikoagulation, DOAK, NOAK, Warfarin, ESC-Leitlinien"
  category: "risk_stratification"
  target_population: "Adults with atrial fibrillation"
  doi: "10.1093/eurheartj/ehad123"
  guideline_year: "2024"
  max_score: "9"
